Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1977 1
1978 3
1980 1
1984 1
1986 2
1987 2
1988 1
1989 1
1990 1
1991 4
1992 2
1993 3
1994 4
1995 7
1996 2
1997 3
1998 3
1999 4
2000 7
2001 3
2002 6
2003 8
2004 9
2005 6
2006 6
2007 13
2008 13
2009 23
2010 33
2011 25
2012 26
2013 20
2014 29
2015 32
2016 20
2017 23
2018 16
2019 21
2020 22
2021 19
2022 18
Text availability
Article attribute
Article type
Publication date

Search Results

397 results
Results by year
Filters applied: . Clear all
Page 1
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators. Hauser SL, et al. N Engl J Med. 2017 Jan 19;376(3):221-234. doi: 10.1056/NEJMoa1601277. Epub 2016 Dec 21. N Engl J Med. 2017. PMID: 28002679 Free article. Clinical Trial.
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.
Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators. Montalban X, et al. N Engl J Med. 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468. Epub 2016 Dec 21. N Engl J Med. 2017. PMID: 28002688 Free article. Clinical Trial.
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L; TRANSFORMS Study Group. Cohen JA, et al. N Engl J Med. 2010 Feb 4;362(5):402-15. doi: 10.1056/NEJMoa0907839. Epub 2010 Jan 20. N Engl J Med. 2010. PMID: 20089954 Free article. Clinical Trial.
Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.
Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, Viglietta V, Dawson KT; CONFIRM Study Investigators. Fox RJ, et al. N Engl J Med. 2012 Sep 20;367(12):1087-97. doi: 10.1056/NEJMoa1206328. N Engl J Med. 2012. PMID: 22992072 Free article. Clinical Trial.
Iron and Parasites.
Arroyo R, Ochoa T, Tai JH, de la Garza M. Arroyo R, et al. Biomed Res Int. 2015;2015:291672. doi: 10.1155/2015/291672. Epub 2015 May 20. Biomed Res Int. 2015. PMID: 26078944 Free PMC article. No abstract available.
Vitamin D, smoking, EBV, and long-term cognitive performance in MS: 11-year follow-up of BENEFIT.
Cortese M, Munger KL, Martínez-Lapiscina EH, Barro C, Edan G, Freedman MS, Hartung HP, Montalbán X, Foley FW, Penner IK, Hemmer B, Fox EJ, Schippling S, Wicklein EM, Kappos L, Kuhle J, Ascherio A; BENEFIT Study Group. Cortese M, et al. Neurology. 2020 May 5;94(18):e1950-e1960. doi: 10.1212/WNL.0000000000009371. Epub 2020 Apr 16. Neurology. 2020. PMID: 32300060 Free PMC article. Clinical Trial.
Nefrologia: International Journal.
Portillo JM, Arroyo RA. Portillo JM, et al. Among authors: arroyo ra. Nefrologia. 2015;35(2):125-6. doi: 10.1016/j.nefro.2015.05.011. Epub 2015 Jun 23. Nefrologia. 2015. PMID: 26300503 Free article. English, Spanish. No abstract available.
Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.
Confavreux C, O'Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, Wolinsky JS, Bagulho T, Delhay JL, Dukovic D, Truffinet P, Kappos L; TOWER Trial Group. Confavreux C, et al. Lancet Neurol. 2014 Mar;13(3):247-56. doi: 10.1016/S1474-4422(13)70308-9. Epub 2014 Jan 23. Lancet Neurol. 2014. PMID: 24461574 Clinical Trial.
Hypomimia in Parkinson's Disease: What Is It Telling Us?
Maycas-Cepeda T, López-Ruiz P, Feliz-Feliz C, Gómez-Vicente L, García-Cobos R, Arroyo R, García-Ruiz PJ. Maycas-Cepeda T, et al. Among authors: arroyo r. Front Neurol. 2021 Jan 25;11:603582. doi: 10.3389/fneur.2020.603582. eCollection 2020. Front Neurol. 2021. PMID: 33569034 Free PMC article.
397 results